Vraylar (cariprazine) is an atypical antipsychotic prescribed for three main conditions: schizophrenia, bipolar I disorder, and major depressive disorder. It’s taken as a once-daily capsule and works by fine-tuning dopamine activity in the brain rather than simply blocking it, which sets it apart from many older antipsychotics.
Schizophrenia
Vraylar was first approved in 2015 for treating schizophrenia in adults. Clinical trials tested it in patients aged 18 to 60, and it showed significant improvement in both positive symptoms (like hallucinations and delusions) and negative symptoms (like social withdrawal and flat emotional expression). The starting dose is 1.5 mg daily, with a maximum of 6 mg daily.
The fact that Vraylar helps with negative symptoms is notable. Many antipsychotics are effective at reducing hallucinations and paranoia but do little for the emotional blunting, lack of motivation, and social disconnection that often cause the most day-to-day difficulty. Vraylar’s unusually strong binding to a specific type of dopamine receptor (D3) is thought to be the reason it addresses these symptoms more effectively than some alternatives.
Bipolar I Disorder
Vraylar treats bipolar I disorder on both ends of the mood spectrum: manic/mixed episodes and depressive episodes.
Manic and Mixed Episodes
For acute mania, clinical trials showed improvements in mania scores as early as day four of treatment. About 52% of patients reached remission on Vraylar, compared with 35% on placebo. Manic symptoms improved by roughly 59% with the medication versus 44% with placebo. Both lower and higher dose ranges proved effective.
Depressive Episodes
Bipolar depression is notoriously difficult to treat, and relatively few medications are approved for it. Vraylar at 1.5 mg daily significantly reduced depressive symptoms in clinical trials. The 3 mg dose showed some reduction as well, though the results were less consistent. For bipolar depression, the maximum recommended dose is 3 mg daily, lower than the doses used for mania or schizophrenia.
Add-On Treatment for Major Depression
Vraylar’s most recent approval is for major depressive disorder (MDD) as an add-on to an antidepressant that isn’t working well enough on its own. This isn’t a first-line treatment. It’s specifically for people who’ve tried at least one antidepressant at an adequate dose for at least six weeks and haven’t seen enough improvement.
In a large clinical trial, adding Vraylar 1.5 mg to an existing antidepressant produced a significantly greater reduction in depression scores than adding a placebo. About 44% of patients met response criteria with Vraylar 1.5 mg, compared with 35% on placebo. Remission rates, however, weren’t significantly different between groups, meaning the medication helped more people improve but didn’t necessarily bring them all the way to symptom-free. Weight gain was minimal, averaging less than 1 kg across all groups.
How Vraylar Works Differently
Most antipsychotics work by blocking dopamine receptors. Vraylar takes a different approach. It’s a partial agonist, meaning it dials dopamine activity up or down depending on what’s happening in a given brain circuit. In areas where dopamine is too active (linked to psychosis and mania), it tones things down. In areas where dopamine is too low (linked to depression and negative symptoms), it provides a mild boost.
Vraylar binds to D3 dopamine receptors with about 10 times the affinity it has for D2 receptors. This preference for D3 receptors is stronger than any other available antipsychotic and likely explains its broader symptom coverage across conditions.
Common Side Effects
The most frequently reported side effects involve movement-related symptoms. In schizophrenia trials, 15% to 19% of patients experienced some form of involuntary muscle stiffness, tremor, or restlessness (compared with 8% on placebo). Akathisia, a specific type of inner restlessness that makes it hard to sit still, affected 9% to 13% of patients.
In bipolar mania trials, these rates were higher: movement-related symptoms occurred in 26% to 29% of patients, and akathisia in about 20%. Other common side effects in the mania trials included vomiting (8% to 10%), indigestion (7% to 9%), drowsiness (7% to 8%), and general restlessness (7%). Insomnia and headache are also commonly reported across conditions, each affecting roughly 7% to 17% of patients depending on the study.
The Unusually Long Half-Life
One thing that makes Vraylar unique among antipsychotics is how long it stays in your system. The drug itself has a half-life of roughly 3 to 6 days, but its main active breakdown product lingers for 2 to 3 weeks. This has practical consequences in both directions.
On the positive side, missing a single dose is less likely to cause a sudden return of symptoms compared with shorter-acting medications. On the other hand, if you experience a side effect, it won’t go away quickly after stopping the drug. It also means that when your prescriber adjusts your dose, the full effect of that change may not be apparent for several weeks. This is why monitoring is typically recommended for an extended period after any dose change, longer than with most other medications in this class.
Who Vraylar Is Not For
Vraylar is approved only for adults. Safety and effectiveness in children and adolescents have not been established, though the FDA has formally requested that the manufacturer conduct pediatric studies for schizophrenia (ages 13 to 17), bipolar I disorder (ages 10 to 17), and irritability associated with autism spectrum disorder (ages 5 to 17). Those studies are underway but not yet complete.
Like all atypical antipsychotics, Vraylar carries a boxed warning (the FDA’s most serious safety alert) regarding use in elderly patients with dementia-related psychosis, as medications in this class are associated with an increased risk of death in that population. It is not approved for treating dementia-related psychosis.